This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Cramer's Action Alerts PLUS - See his portfolio and get alerts BEFORE every trade. Learn more NOW!

INNATE PHARMA: Launch Of IND-Enabling Studies For IPH4102

  • IPH4102 is a first-in-class drug candidate targeting KIR3DL2, a receptor specifically expressed by some rare forms of cancer  
  • It is developed in an orphan disease, cutaneous T-cell lymphomas, and especially their aggressive forms: Sezary Syndrome and Transformed Mycosis Fungoides  
  • An investigational new drug (IND) application should be submitted in late 2014  
  • Innate Pharma intends to develop IPH4102 as a proprietary program

MARSEILLE, France, Nov. 8, 2013 (GLOBE NEWSWIRE) -- Innate Pharma SA (the "Company" - Euronext Paris: FR0010331421 - IPH), the innate immunity company developing first-in-class drug candidates for cancer and inflammatory diseases, announced today that it had selected and qualified the IPH4102 drug candidate for further development.

IPH4102 is a first-in-class cytotoxic antibody developed in some types of KIR3DL2-expressing cancers, such as the Sezary Syndrome ("SS") and Transformed Mycosis Fungoides ("TMF"), which are aggressive forms of cutaneous T-cell lymphomas. IND-enabling studies and industrial production of the molecule have begun. The IND application is expected to be submitted in late 2014.

Professor Martine Bagot, Head of the Dermatology Department at the Saint-Louis Hospital in Paris, France, said: "We discovered the KIR3DL2 target with Professor Bensussan's team and worked together with Innate Pharma for several years to design this drug candidate. The unmet need in SS and TMF is huge. Due to its original target specifically expressed by the tumor cells, IPH4102 has a unique potential for being both very active and well tolerated".

"We plan to develop IPH4102 in cutaneous T-cell lymphomas expressing KIR3DL2 in close collaboration with referral international centres such as the Saint-Louis Hospital" added Marcel Rozencweig, Chief Medical Officer at Innate Pharma. "These are orphan diseases and their more devastating forms could particularly benefit from a treatment using IPH4102".

A poster on IPH4102 is presented today at the Annual Meeting of the Society for Immunotherapy of Cancer (SITC, 7 - 10 November 2013, National Harbor, MD, United States): "Novel therapeutic and diagnostic antibodies against KIR3DL2, a unique tumour antigen expressed on subtypes of T-Cell Lymphomas", from 1:00 to 2:00 pm and from 6:15 to 7:15 pm, Poster 49.

See poster: http://www.innate-pharma.com/sites/default/files/sitc2013_iph41.pdf

About IPH4102, Sezary Syndrome and Transformed Mycosis Fungoides:

KIR3DL2 is an inhibiting receptor of the KIR superfamily, normally expressed on a minor fraction of normal NK cells but specifically expressed in certain aggressive forms of the orphan indication of cutaneous T-cell lymphomas, such as Transformed Mycosis Fungoides (TMF) and Sezary Syndrome (SS).

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 18,203.37 -85.26 -0.47%
S&P 500 2,107.78 -9.61 -0.45%
NASDAQ 4,979.9010 -28.1950 -0.56%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs